secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2023-02-16T23:59:59+00:00
Accession:  0001564590-23-001975
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes FY2022 revenue $1.11B, GAAP loss per share $0.97; guides FY2023 revenue $1.13-1.25B
--------------------------------------------------------------------------------

- Q4 2022 total revenues $304.7M, GAAP net loss $0.17/share, non-GAAP diluted EPS $0.14.
- FY2022 proprietary net sales: VIVITROL $379.5M (+10%), ARISTADA $302.1M (+10%), LYBALVI $96.0M (first full year).
- FY2023 guidance: revenue $1.13-$1.25B, GAAP loss per share ($0.96)-($1.20), non-GAAP diluted EPS $0.00-$0.23.
- New long-term profitability targets: FY2024 non-GAAP net income 25% of revenue, EBITDA margin 20%; FY2025 30% and 25%.
- Plans to separate oncology business in H2 2023; arbitration with Janssen ongoing, interim award in company's favor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000156459023001975/0001564590-23-001975-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000156459023001975/alks-8k_20230216.htm
  HTML page:      https://secwatch.observer/filing/0001564590-23-001975

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer